Stefan Platz, Roche
I started off as a pathologist at Boehringer-Ingelheim in Germany.
Stefan Platz
Head of Toxicology, Non-Clinical Safety Global Head, Early Safety, Roche
I started off as a pathologist at Boehringer-Ingelheim in Germany. When I accepted the position as the head of Non-Clinical Safety in Palo Alto, CA, and moved from a classical German culture to Silicon Valley, I was amazed by the speed and the innovative culture around me. It was a very stimulating and interesting environment.
There is the expectation that younger leaders will come into the industry with a more creative mindset, open to new ideas and concepts of innovation. There are many exciting innovations likely to occur in the coming years, especially in the development of new technologies. One very interesting emerging technology is the field of small interfering RNA (siRNA). Compared to small molecules, siRNA offers the opportunity to be more selective and potent against a well-defined target.
I sought a career to find cures to diseases and help patients around the world. It was and still is enticing to be part of a team that develops drugs that one day will save lives.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
